Skip to main content
ENDO 2026 Main banner

Pediatric and Adolescent Endocrinology

SY52-02 - New Implications in the Endocrine Care of Achondroplasia

Monday, June 15, 2026
5:00 PM - 5:30 PM CT
Location: Room W187
Disclosure(s):
Nadia Merchant, MD, FAAP, FACMG: Alexion Pharmaceutical: Advisory Board (), Honorarium Recipient (); Ascendis Pharma: Advisory Board (), Clinical Trial Investigator (); BioMarin: Advisory Board (), Clinical Trial Investigator (), Honorarium Recipient (); BridgeBio: Advisory Board (), Clinical Trial Investigator (), Honorarium Recipient (); Catalyst: Advisory Board (), Honorarium Recipient (); Kyowa Kirin: Advisory Board (), Honorarium Recipient (); Tyra: Clinical Trial Investigator (); UltraGenyx: Advisory Board (), Honorarium Recipient ()
Growth disorders are among the leading consultations with pediatric endocrinologists due to their potential impact on children’s health. The etiology of growth disorders is multiple and heterogeneous, leading to distinct strategies and scenarios depending on the subjacent cause. Despite the long experience with daily growth hormone, novelties on growth-promoting therapies have emerged recently. This session will adresss current knowledge and therapeutic advances on distinct clinical settings of growth failure, emphasizing the best practice for pediatric patients care.

Learning Objectives:

  • manage endocrine care of achondroplasia linked to recent availability of new therapeutics,
  • manage growth failure in children with imprinting disorders, addressing aspects of therapeutics (growth, metabolism, nutritional status),